Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ZIM Integrated Shipping Services Ltd. (ZIM) : This container shipping provider has seen the Zacks Consensus Estimate for its current year earnings increasing 41.7% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.9% over the last 60 days.Rush Street Interactive, Inc. (RSI) : This online casino and sports betting company has ...

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the last trading session at $34.31, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.93 indicates an 112.6% upside potential.The average comprises 15 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $18.74. While the lowest estimate indicates a decline of 30.1% fro ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.                   Guggenheim Securities Heal ...

Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | --- | --- | |-------- ...

公司财务业绩 - 2024年第三季度KIMMTRAK净营收8020万美元较2023年第三季度增长28% [1] - 2024年第三季度每股收益0.17美元2023年第三季度为0.02美元 [1][20] - 2024年第三季度净产品销售额8020万美元2023年同期为6260万美元主要源于美国销量增加和全球市场扩张 [18] - 2024年第三季度研发费用5280万美元2023年同期为4320万美元增长主要源于tebentafusp项目费用 [19] - 2024年第三季度销售管理费用3550万美元与2023年同期持平 [19] - 2024年9月30日现金现金等价物和有价证券为9.013亿美元计划年底偿还5000万美元贷款并支付约4000万美元销售相关回扣应计费用 [21] 公司业务进展 - KIMMTRAK已在38个国家获批在21个国家推出公司认为其在转移性葡萄膜黑色素瘤持续扩张潜在扩展到二线以上晚期皮肤黑色素瘤和辅助性葡萄膜黑色素瘤三个关键增长领域 [3] - 转移性葡萄膜黑色素瘤方面2024年前三季度净产品销售额分别为8020万美元和2.259亿美元较上年同期分别增长28%和32%美国和德国增长源于需求增加 [4] - 二线以上既往治疗过的皮肤黑色素瘤方面TEBE - AM三期试验持续随机分组预计2026年上半年完成随机分组主要终点为总生存期 [5] - 辅助性葡萄膜黑色素瘤方面ATOM三期试验预计2024年第四季度开始随机分组是目前唯一活跃的辅助性葡萄膜黑色素瘤注册性三期试验 [5] - Brenetafusp方面PRISM - MEL - 301一期试验持续随机分组评估brenetafusp + nivolumab与nivolumab或nivolumab + relatlimab对照臂一期/二期临床试验评估单药及联合用药 [6][7] - 卵巢癌方面一期试验数据显示单药患者疾病控制率58%联合用药患者69%单药队列6个月总生存率73% [8] - IMC - P115C预计2025年上半年开始一期试验治疗首位患者 [9] - IMC - R117C用于结直肠癌和其他胃肠道癌症计划2024年第四季度开始一期/二期试验评估安全性和临床活性 [10][11] - 传染病方面IMC - M113V用于HIV感染患者的一期试验已达到生物活性剂量正在招募更多患者IMC - I109V用于HBV感染患者的一期试验预计2024年第四季度完成单剂量递增部分 [12][13][14] - 自身免疫疾病方面公司有两个新的双特异性候选药物进入研发管线IMC - S118AI用于1型糖尿病未公开的非HLA限制候选药物用于炎症性皮肤病 [15][16] - 公司CFO兼战略主管Brian Di Donato计划年底离职公司正在寻找新的CFO [17]

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estima ...

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pretreated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in blood is an important parameter of clinical activity for tebentafusp in uveal melanoma and for brenetafusp across different tumor types (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., ...

文章核心观点 - 公司是一家商业化阶段的生物技术公司,专注于开发创新的免疫调节药物,以改善癌症、感染性疾病和自身免疫性疾病患者的治疗结果[1][2] - 公司将参加2024年Cantor全球医疗保健大会,并进行现场直播演讲[1] 公司概况 - 公司开发了一种名为ImmTAX的新型TCR双特异性免疫疗法平台,可用于治疗多种疾病,包括癌症、自身免疫性疾病和感染性疾病[2] - 公司拥有丰富的临床和临床前管线,包括5个临床阶段的肿瘤和感染性疾病项目,以及多个自身免疫性疾病和早期临床前项目[2] - 公司最先进的肿瘤TCR疗法KIMMTRAK已获得美国、欧盟、加拿大、澳大利亚和英国的批准,用于治疗HLA-A*02:01阳性的不可切除或转移性葡萄膜黑色素瘤成人患者[2]

Bevan Goldswain/E+ via Getty Images Immunocore (NASDAQ:IMCR) has made significant progress in being able to use its proprietary ImmTAX platform to develop T-cell receptors [TCRs] against a variety of types of cancer. It has already received FDA approval of Kimmtrak for the treatment of patients with advanced or metastatic uveal melanoma who are HLAA*02:01-positive. Sales for this drug franchise continue to climb, especially when you consider the reported number. It was stated that in Q2 of 2024, sales of Ki ...